FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470
The FDA has granted approval for ANDA219470, a generic version of Diphenhydramine Hydrochloride by Annora Pharma.
Published: June 24, 2026
Updated: June 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Allergy / Antihistamine
Company: Annora Pharma
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Annora Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Annora Pharma and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.